18 results match your criteria: "the Center for Psychiatric Neuroscience[Affiliation]"

Development of lateral pulvinar resting state functional connectivity and its role in attention.

Cortex

March 2021

Department of Psychiatry, Zucker Hillside Hospital, Northwell Health System, NY, United States; Center for Psychiatric Neuroscience, Feinstein Institutes for Medical Research, Manhasset, NY, United States; Department of Psychiatry, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, United States. Electronic address:

Objective: The lateral pulvinar nucleus (LPN) has a well-established role in visual attention. Oscillatory activity of the LPN is critical for cortico-cortical communication within and among occipital and temporal visual processing regions. However, the functional development of the LPN and its role in attention deficits is not understood.

View Article and Find Full Text PDF

Evidence from both GWAS and clinical observation has suggested that certain psychiatric, metabolic, and autoimmune diseases are heterogeneous, comprising multiple subtypes with distinct genomic etiologies and Polygenic Risk Scores (PRS). However, the presence of subtypes within many phenotypes is frequently unknown. We present CLiP (Correlated Liability Predictors), a method to detect heterogeneity in single GWAS cohorts.

View Article and Find Full Text PDF

Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis.

Am J Psychiatry

January 2019

From the Departments of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y.; the Division of Psychiatry Research, Northwell Health, Zucker Hillside Hospital, Glen Oaks, N.Y.; the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, N.Y.; New York-Presbyterian/Westchester Division, Weill Cornell Medical College, White Plains, N.Y.; Medical University Innsbruck, Austria; Icahn School of Medicine at Mount Sinai, New York; and the Department of Medicine and Psychiatry, University of Cantabria, CIBERSAM, IDIVAL, University Hospital Marqués de Valdecilla, Santander, Spain.

Objective: Pharmacogenomic studies of antipsychotics have typically examined effects of individual polymorphisms. By contrast, polygenic risk scores (PRSs) derived from genome-wide association studies (GWAS) can quantify the influence of thousands of common alleles of small effect in a single measure. The authors examined whether PRSs for schizophrenia were predictive of antipsychotic efficacy in four independent cohorts of patients with first-episode psychosis (total N=510).

View Article and Find Full Text PDF

Targeting Obsessive-Compulsive Symptoms With rTMS and Perfusion Imaging.

Am J Psychiatry

January 2018

From the Translational Research Center, University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland; Psychiatric University Hospital Zurich, Switzerland; and the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Hofstra Northwell School of Medicine, New York.

View Article and Find Full Text PDF

Marijuana use is associated with psychosis, but its effects are understudied in individuals with preexisting risk for psychotic disorders. This preliminary study examined the acute psychological and physiological effects of smoked marijuana (0.0% or 5.

View Article and Find Full Text PDF

In Support of Neuroimaging Biomarkers of Treatment Response in First-Episode Schizophrenia.

Am J Psychiatry

July 2016

From the Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, N.Y.; the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, N.Y.; and the Department of Psychiatry, Hofstra Northwell School of Medicine, Hempstead, N.Y.

View Article and Find Full Text PDF

Personalized Prediction of Psychosis: External Validation of the NAPLS-2 Psychosis Risk Calculator With the EDIPPP Project.

Am J Psychiatry

October 2016

From the Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, Glen Oaks, N.Y.; the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Northwell Health, Manhasset, N.Y.; the Departments of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, N.Y.; the Department of Psychiatry, University of Michigan, Ann Arbor; the Department of Psychiatry, Stanford University, Palo Alto, Calif.; the Imaging Research Center and the Center for Neuroscience, University of California Davis, Sacramento, Calif.; Portland State University Regional Research Institute, Portland, Ore.; the Mid-Valley Behavioral Care Network, Marion County Health Department, Salem, Ore.; Tufts University School of Medicine, Boston; and Maine Medical Center Research Institute, Portland.

Objective: As part of the second phase of the North American Prodrome Longitudinal Study (NAPLS-2), Cannon and colleagues report, concurrently with the present article, on a risk calculator for the individualized prediction of a psychotic disorder in a 2-year period. The present study represents an external validation of the NAPLS-2 psychosis risk calculator using an independent sample of patients at clinical high risk for psychosis collected as part of the Early Detection, Intervention, and Prevention of Psychosis Program (EDIPPP).

Method: Of the total EDIPPP sample of 210 subjects rated as being at clinical high risk based on the Structured Interview for Prodromal Syndromes, 176 had at least one follow-up assessment and were included in the construction of a new prediction model with six predictor variables in the NAPLS-2 psychosis risk calculator (unusual thoughts and suspiciousness, symbol coding test performance, verbal learning test performance, decline in social functioning, baseline age, and family history).

View Article and Find Full Text PDF

Health Technology Intervention After Hospitalization for Schizophrenia: Service Utilization and User Satisfaction.

Psychiatr Serv

September 2016

Dr. Baumel, Dr. Correll, Dr. Hauser, Dr. Schooler, Dr. Robinson, Ms. Marcy, and Dr. Kane are with the Department of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York (e-mail: ). Dr. Baumel, Dr. Correll, Dr. Robinson, and Dr. Kane are also with Hofstra Northwell School of Medicine, Hempstead, New York. Dr. Hauser and Ms. Marcy are also with the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, New York. Dr. Schooler is also with the Department of Psychiatry and Behavioral Sciences, SUNY Downstate Medical Center, Brooklyn, New York. Dr. Brunette and Dr. Ben-Zeev are with the Center for Technology and Behavioral Health, Dartmouth Psychiatric Research Center, Geisel School of Medicine at Dartmouth College, Lebanon, New Hampshire. Dr. Rotondi is with the Department of Critical Care Medicine, Clinical and Translational Sciences Institute, Pittsburgh, and with the Mental Illness Research, Education and Clinical Center, U.S. Department of Veterans Affairs Medical Center, Pittsburgh. Dr. Gottlieb and Dr. Mueser are with the Center for Psychiatric Rehabilitation, Boston University, Boston. Dr. Achtyes is with Cherry Health and Michigan State University College of Human Medicine, East Lansing. Ms. Gingerich is an independent consultant and trainer in Narberth, Pennsylvania. Dr. Meyer-Kalos is with the Department of Social Work, Minnesota Center for Chemical and Mental Health, St. Paul.

Objective: The authors examined patients' acceptance of the Health Technology Program (HTP), an integrative approach to relapse prevention after hospitalization of adults with schizophrenia or related disorders. The program combines use of digital tools with support from a mental health technology coach (MHTC).

Methods: Patients with schizophrenia spectrum disorders received six months of treatment that began within 60 days of a psychiatric hospitalization and included the development of a personalized relapse prevention plan, three digital tools, and contacts with MHTCs.

View Article and Find Full Text PDF

Responses to Tobacco Smoking-Related Health Messages in Young People With Recent-Onset Schizophrenia.

Schizophr Bull

November 2015

The Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY; Division of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, NY; Departments of Psychiatry and Molecular Medicine, Hofstra-LIJ School of Medicine, Hempstead, NY;

Virtually no research has examined the responses of youth with recent-onset psychosis (ROP) to smoking-related health warnings. We examined predictors of response and tested hypotheses that participants with ROP would (a) assess warnings as less effective than a healthy comparison (HC) group, and (b) assess video warnings as more effective than pictures. ROP participants (n = 69) had <2 years of prior antipsychotic treatment; the HC group (n = 79) had no major mental illness.

View Article and Find Full Text PDF

Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment.

Am J Psychiatry

January 2016

From the Department of Psychiatry, Zucker Hillside Hospital, North Shore-LIJ Health System, Glen Oaks, N.Y.; the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, N.Y.; the Department of Psychiatry, Hofstra North Shore-LIJ School of Medicine, Hempstead, N.Y.; and the Department of Mathematics, Hofstra University, Hempstead, N.Y.

Objective: Clinical response to antipsychotic drug treatment is highly variable, yet prognostic biomarkers are lacking. The authors recently demonstrated that successful antipsychotic drug treatment alters resting-state functional connectivity of the striatum. The goal of the present study was to test whether intrinsic striatal connectivity patterns provide prognostic information and can serve as a potential biomarker of treatment response to antipsychotic drugs.

View Article and Find Full Text PDF

Psychosis Prevention: A Modified Clinical High Risk Perspective From the Recognition and Prevention (RAP) Program.

Am J Psychiatry

October 2015

From the Division of Psychiatry Research, Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, Glen Oaks, N.Y.; the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System, Manhasset, N.Y.; and the Department of Psychiatry and Molecular Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, N.Y.

Objective: Early intervention and prevention of psychosis remain a major challenge. Prediction would be greatly advanced with improved ability to identify individuals at true risk, which, at present, is moderate at best. The authors tested a modified strategy to improve prediction by selecting a more homogeneous high-risk sample (attenuated positive symptom criteria only, age range of mid-teens to early 20s) than is currently standard, combined with a systematic selection of neurodevelopmental deficits.

View Article and Find Full Text PDF

Response to Saraga.

Am J Psychiatry

June 2015

From the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, N.Y.; the Departments of Psychiatry and of Molecular Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, N.Y.; The Zucker Hillside Hospital, Glen Oaks, N.Y.; and the Department of Psychiatry, SUNY Downstate Medical Center, Brooklyn, N.Y.

View Article and Find Full Text PDF

Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study.

Am J Psychiatry

March 2015

From the Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, N.Y.; the Departments of Psychiatry and Molecular Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, N.Y.; Psychiatry Research, Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, Glen Oaks, N.Y.; SUNY Downstate Medical Center, New York; Albert Einstein College of Medicine, Bronx, N.Y.; Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Canada; Geisel School of Medicine, Dartmouth, N.H.; the Departments of Social Medicine and Psychology, University of North Carolina, Chapel Hill; the Center for Psychiatric Rehabilitation, Departments of Occupational Therapy, Psychiatry, and Psychology, Boston University, Boston; the Nathan S. Kline Institute for Psychiatric Research, Orangeburg, N.Y.; the Department of Psychiatry and Adolescent and Child Psychiatry, New York University Langone Medical Center, New York; the Departments of Psychiatry and Epidemiology and Public Health, Yale School of Medicine, New Haven, Conn.; and NIMH, Bethesda, Md.

Objective: Treatment guidelines suggest distinctive medication strategies for first-episode and multiepisode patients with schizophrenia. To assess the extent to which community clinicians adjust their usual treatment regimens for first-episode patients, the authors examined prescription patterns and factors associated with prescription choice in a national cohort of early-phase patients.

Method: Prescription data at study entry were obtained from 404 participants in the Recovery After an Initial Schizophrenia Episode Project's Early Treatment Program (RAISE-ETP), a nationwide multisite effectiveness study for patients with first-episode schizophrenia spectrum disorders.

View Article and Find Full Text PDF

Control of mitochondrial pH by uncoupling protein 4 in astrocytes promotes neuronal survival.

J Biol Chem

November 2014

From the School of Life Sciences, Brain Mind Institute, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland, the Center for Psychiatric Neuroscience, 1008 Prilly-Lausanne, Switzerland

Brain activity is energetically costly and requires a steady and highly regulated flow of energy equivalents between neural cells. It is believed that a substantial share of cerebral glucose, the major source of energy of the brain, will preferentially be metabolized in astrocytes via aerobic glycolysis. The aim of this study was to evaluate whether uncoupling proteins (UCPs), located in the inner membrane of mitochondria, play a role in setting up the metabolic response pattern of astrocytes.

View Article and Find Full Text PDF

Disrupted resting-state functional connectivity in minimally treated chronic schizophrenia.

Schizophr Res

July 2014

State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University, Beijing 100875, China. Electronic address:

Objective: The pathophysiology of chronic schizophrenia may reflect long term brain changes related to the disorder. The effect of chronicity on intrinsic functional connectivity patterns in schizophrenia without the potentially confounding effect of antipsychotic medications, however, remains largely unknown.

Method: We collected resting-state fMRI data in 21 minimally treated chronic schizophrenia patients and 20 healthy controls.

View Article and Find Full Text PDF

Rnd1 regulates axon extension by enhancing the microtubule destabilizing activity of SCG10.

J Biol Chem

January 2009

Abteilung Molekularbiologie, Institut fu¨r Allgemeine Zoologie und Genetik, Westfa¨lische Wilhelms-Universita¨t Mu¨nster, Schloßplatz 5, D-48149 Mu¨nster, Germany and the Center for Psychiatric Neuroscience, Department of Psychiatry-Centre Hospitalier Universitaire Vaudois, University of Lausanne, 1008 Prilly, Switzerland. Electronic address:

The GTPase Rnd1 affects actin dynamics antagonistically to Rho and has been implicated in the regulation of neurite outgrowth, dendrite development, and axon guidance. Here we show that Rnd1 interacts with the microtubule regulator SCG10. This interaction requires a central domain of SCG10 comprising about 40 amino acids located within the N-terminal-half of a putative alpha-helical domain and is independent of phosphorylation at the four identified phosphorylation sites that regulate SCG10 activity.

View Article and Find Full Text PDF

A pathogenetic model of autism involving Purkinje cell loss through anti-GAD antibodies.

Med Hypotheses

August 2008

Departments of Surgery, Physiology and Biophysics, The Center for Psychiatric Neuroscience, University of Mississippi Medical Center, Jackson, MS 39216-4505, United States.

Autism is a medical enigma, lacking truly effective treatments. Both genetics and environmental factors are recognized as players in the development of autism spectrum disorders (ASDs). Nevertheless, the exact mechanism(s) for the development of ASDs is (are) not known primarily because current understanding about the etiology of the disease is limited.

View Article and Find Full Text PDF